These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11342436)

  • 1. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome.
    Karpman D; Papadopoulou D; Nilsson K; Sjögren AC; Mikaelsson C; Lethagen S
    Blood; 2001 May; 97(10):3100-8. PubMed ID: 11342436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced low shear stress induced platelet aggregation by Shiga-like toxin 1 purified from Escherichia coli O157.
    Yagi H; Narita N; Matsumoto M; Sakurai Y; Ikari H; Yoshioka A; Kita E; Ikeda Y; Titani K; Fujimura Y
    Am J Hematol; 2001 Feb; 66(2):105-15. PubMed ID: 11421288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways.
    Liu F; Huang J; Sadler JE
    Blood; 2011 Sep; 118(12):3392-8. PubMed ID: 21816831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.
    Ståhl AL; Sartz L; Karpman D
    Blood; 2011 May; 117(20):5503-13. PubMed ID: 21447825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet thrombus formation in eHUS is prevented by anti-MBL2.
    Kushak RI; Boyle DC; Rosales IA; Ingelfinger JR; Stahl GL; Ozaki M; Colvin RB; Grabowski EF
    PLoS One; 2019; 14(12):e0220483. PubMed ID: 31881024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome.
    Ståhl AL; Sartz L; Nelsson A; Békássy ZD; Karpman D
    PLoS One; 2009 Sep; 4(9):e6990. PubMed ID: 19750223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome.
    Tazzari PL; Ricci F; Carnicelli D; Caprioli A; Tozzi AE; Rizzoni G; Conte R; Brigotti M
    Cytometry B Clin Cytom; 2004 Sep; 61(1):40-4. PubMed ID: 15351981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD40 Ligand and Oxidative Response Are Reciprocally Stimulated during Shiga Toxin-Associated Hemolytic Uremic Syndrome.
    Abrey Recalde MJ; Alvarez RS; Alberto F; Mejias MP; Ramos MV; Fernandez Brando RJ; Bruballa AC; Exeni RA; Alconcher L; Ibarra CA; Amaral MM; Palermo MS
    Toxins (Basel); 2017 Oct; 9(11):. PubMed ID: 29068360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The A1 Subunit of Shiga Toxin 2 Has Higher Affinity for Ribosomes and Higher Catalytic Activity than the A1 Subunit of Shiga Toxin 1.
    Basu D; Li XP; Kahn JN; May KL; Kahn PC; Tumer NE
    Infect Immun; 2016 Jan; 84(1):149-61. PubMed ID: 26483409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shiga toxin binds to activated platelets.
    Ghosh SA; Polanowska-Grabowska RK; Fujii J; Obrig T; Gear AR
    J Thromb Haemost; 2004 Mar; 2(3):499-506. PubMed ID: 15009469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escherichia coli Shiga toxin.
    Nakao H; Takeda T
    J Nat Toxins; 2000 Aug; 9(3):299-313. PubMed ID: 10994531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical and bacteriological study of children suffering from haemolytic uraemic syndrome in Tucuman, Argentina.
    Miceli S; Jure MA; de Saab OA; de Castillo MC; Rojas S; de Holgado AP; de Nader OM
    Jpn J Infect Dis; 1999 Apr; 52(2):33-7. PubMed ID: 10816611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
    Arvidsson I; Ståhl AL; Hedström MM; Kristoffersson AC; Rylander C; Westman JS; Storry JR; Olsson ML; Karpman D
    J Immunol; 2015 Mar; 194(5):2309-18. PubMed ID: 25637016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome.
    Nestoridi E; Tsukurov O; Kushak RI; Ingelfinger JR; Grabowski EF
    J Thromb Haemost; 2005 Apr; 3(4):752-62. PubMed ID: 15842359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.
    Tremblay JM; Mukherjee J; Leysath CE; Debatis M; Ofori K; Baldwin K; Boucher C; Peters R; Beamer G; Sheoran A; Bedenice D; Tzipori S; Shoemaker CB
    Infect Immun; 2013 Dec; 81(12):4592-603. PubMed ID: 24082082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
    Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
    Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome.
    Ludwig K; Karmali MA; Sarkim V; Bobrowski C; Petric M; Karch H; Müller-Wiefel DE;
    J Clin Microbiol; 2001 Jun; 39(6):2272-9. PubMed ID: 11376069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes.
    Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA
    Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli shiga toxins in non-human primate models of hemolytic uremic syndrome.
    Stearns-Kurosawa DJ; Oh SY; Cherla RP; Lee MS; Tesh VL; Papin J; Henderson J; Kurosawa S
    Am J Pathol; 2013 Apr; 182(4):1227-38. PubMed ID: 23402998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
    J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.